Clinical trialNAActive not recruiting
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
Helping Oncology Patients Explore-Genomics (HOPE-Genomics) Web Tool Randomized Clinical Trial
- Outcome
- Ongoing
- Phase
- NA
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 30 December 2021
- Expected end
- 1 October 2026
- Enrollment
- 465 participants
- Sites
- 1
- Primary outcomes
- Recall Rates of Personal Genomic Results
- Sponsor
- Other
- Results posted
- 2025-12-11
- Last update
- 11 September 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This clinical trial studies the effectiveness of a web-based cancer education tool called Helping Oncology Patients Explore Genomics (HOPE-Genomics) in improving patient knowledge of personal genomic testing results and cancer and genomics in general. HOPE-Genomics is a web-based education tool that teaches cancer/leukemia patients, and patients who may be at high-risk for developing cancer, about genomic testing and provide patients with information about their own genomic test results. The HOPE-Genomics tool may improve patient's genomic knowledge and quality of patient-centered care. In addition, it may also improve education and care quality for future patients.
Detailed description public domain (ClinicalTrials.gov)
PRIMARY OBJECTIVES: I. Test the efficacy of the HOPE-Genomics intervention in improving patient knowledge of genomics. II. Test the efficacy of the HOPE-Genomics intervention in improving patient receipt of guideline-concordant care. OUTLINE: Patients are randomized to 1 of 3 arms. ARM I (USUAL CARE): Patients receive education pamphlet about whole-genome sequencing (WES) and have their genomics test results returned by their clinician in a typical manner. ARM II (RETURN OF RESULTS ONLY): Patients receive their genomics test results both from their clinician and from the HOPE-Genomics tool. Patients then view HOPE-Genomics tool over 15-20 minutes after their results are available. ARM III (RETURN OF RESULTS PLUS PRE-TEST EDUCATION): Patients view HOPE-Genomics tool (containing educational content) over 15-20 minutes before their sequencing results are available. Patients also receive their genomics test results both from their clinician and from the HOPE-Genomics tool. After completion of study intervention, patients are followed up at 2 weeks, 3 and 9 months after receiving genomic test results.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Recall Rates of Personal Genomic Results [Up to 3 months]. Count Of Participants, Participants. Recalled Germline Testing: Arm I (Usual Care) (n=132): 89; Arm II (Genomics Test Results, HOPE-Genomics) Plus Arm III (HOPE-Genomics, Genomics Test Results) (n=137): 82; Arm III (HOPE-Genomics, Genomics Test Results) (n=131): 83. Not Recalled Germline Testing: Arm I (Usual Care) (n=132): 43; Arm II (Genomics Test Results, HOPE-Genomics) Plus Arm III (HOPE-Genomics, Genomics Test Results) (n=137): 55; Arm III (HOPE-Genomics, Genomics Test Results) (n=131): 48.